Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term - Summary - MDSpire

Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term

  • By

  • Sergio Cortelazzo

  • Michael Mian

  • Andrea Evangelista

  • Liliana Devizzi

  • Paolo Corradini

  • Michele Magni

  • Marco Ladetto

  • Simone Ferrero

  • Andrea Rossi

  • Anna Maria Barbui

  • Caterina Patti

  • Alessandro Costa

  • Umberto Vitolo

  • Annalisa Chiappella

  • Fabio Benedetti

  • Andrés J. M. Ferreri

  • Paolo Nicoli

  • Luigi Rigacci

  • Claudia Castellino

  • Alessandro M. Gianni

  • Alessandro Rambaldi

  • Corrado Tarella

  • July 7, 2021

  • 0 min

Share

Objective:

To determine the long-term efficacy and late clinical complications associated with an intensive chemo-immunotherapy program in adult patients with mantle cell lymphoma (MCL), with a focus on survival outcomes.

Key Findings:
  • 85% of patients achieved complete or unconfirmed complete response at the end of treatment.
  • 7-year overall survival (OS) rate was 67%, significantly influenced by MIPI risk scores.
  • 7-year progression-free survival (PFS) rate was 53.2%, also significantly influenced by MIPI scores.
Interpretation:

Intensive chemo-immunotherapy with autograft significantly improves long-term survival in MCL patients, with MIPI scores being critical prognostic factors that should be considered in clinical practice.

Limitations:
  • Retrospective design may introduce bias, potentially affecting the reliability of the findings.
  • Lack of maintenance therapy post-treatment could impact long-term outcomes and warrants further investigation.
Conclusion:

The study demonstrates that intensive upfront chemo-immunotherapy with autograft can lead to prolonged survival and potential cure in MCL patients, emphasizing the importance of prognostic scoring and the need for ongoing research.

Original Source(s)

Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term

  • by Sergio Cortelazzo, Michael Mian, Andrea Evangelista, Liliana Devizzi, Paolo Corradini, Michele Magni, Marco Ladetto, Simone Ferrero, Andrea Rossi, Anna Maria Barbui, Caterina Patti, Alessandro Costa, Umberto Vitolo, Annalisa Chiappella, Fabio Benedetti, Andrés J. M. Ferreri, Paolo Nicoli, Luigi Rigacci, Claudia Castellino, Alessandro M. Gianni, Alessandro Rambaldi, Corrado Tarella

  • July 7, 2021

Related Content

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China

Multi-strategy feature selection and multi-model machine learning for prognostic prediction in primary gastric diffuse large B-cell lymphoma